<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Dosing and administration of parenteral aminoglycosides
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Dosing and administration of parenteral aminoglycosides
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Dosing and administration of parenteral aminoglycosides
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Drew, PharmD, MS, FCCP, FIDP
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David C Hooper, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Allyson Bloom, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Nov 02, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         The traditional approach to parenteral aminoglycoside dosing in adults involves the administration of a weight-based dose divided two to three times daily in patients with normal renal function. The dose is reduced and/or dosing interval extended in patients with decreased renal function or as indicated by measured serum drug concentration(s). Extended-interval aminoglycoside therapy (also known as once-daily aminoglycosides, single daily aminoglycoside dosing, consolidated or high-dose aminoglycoside therapy) utilizes a higher weight-based dose administered at an extended interval (every 24 hours for those with normal renal function and longer for those with renal dysfunction). Extended-interval aminoglycoside therapy (utilizing higher single doses) should not be confused with traditional, intermittent dosing with lower individual doses administered at extended intervals because of renal impairment.
        </p>
        <p>
         This topic discusses the efficacy and safety, patient selection, and implementation of these two dosing strategies. Other (general) information about aminoglycosides is found elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides"
         </a>
         .)
        </p>
        <p>
         This topic refers to dosing of aminoglycosides for the treatment of typical bacterial infections. While the pharmacokinetics of
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         are generally comparable to those of other aminoglycosides, published experience informing the optimal method of dosing (including the use of serum concentration monitoring to adjust therapy) is limited. Dosing of aminoglycosides in the treatment of mycobacterial infections, tularemia, plague, and brucella is discussed in the topics dedicated to those infections.
        </p>
        <p>
         Of note, for most of these situations, with the exception of urinary tract infections, aminoglycosides are most commonly used in combination with other agents, regardless of dosing method. (See
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides", section on 'Clinical use'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H374424261">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The rapid attainment of therapeutic concentrations of aminoglycosides has been correlated with improved patient outcomes. Thus, dosing should be optimized to achieve this effect. Additionally, dosing should be tailored to minimize aminoglycoside toxicity. The following general principles apply to all patients, regardless of whether traditional intermittent versus extended-interval daily dosing strategies are used:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The initial dose and frequency of aminoglycosides is based upon the aminoglycoside chosen, method of administration (ie, traditional intermittent versus extended-interval daily dosing), indication, dosing weight, and renal function.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Dosing adjustments should be based upon the results of serum drug concentration monitoring. Targeted peak serum concentrations are intended to take advantage of the pharmacodynamic properties to optimize the potential for efficacy, while specific trough concentrations are targeted to avoid concentration-related toxicity (primarily nephrotoxicity). For
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         , dosing strategies based on the determination of the area under the time-concentration curve (AUC) have been proposed [
         <a href="#rid1">
          1
         </a>
         ]. (See
         <a class="local">
          'Plazomicin'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intravenous administration of aminoglycosides should occur over at least 30 minutes for traditional intermittent and at least 60 minutes for extended-interval dosing. Because beta-lactams inactivate aminoglycosides in vitro, they should
         <strong>
          not
         </strong>
         be mixed in the same solution [
         <a href="#rid2">
          2
         </a>
         ]. However, the clinical significance of such interactions in vivo is not clear, since the interaction is time and concentration dependent.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H374424569">
         <span class="h2">
          Dosing weight
         </span>
         <span class="headingEndMark">
          —
         </span>
         The first step in aminoglycoside administration, regardless of method of administration, is determination of the dosing weight.
        </p>
        <p>
         Calculation of the dosing weight differs between patients who are underweight, are average weight, and have obesity. Underweight patients have a total body weight (TBW) less than the ideal body weight (IBW). For aminoglycoside dosing, obesity is defined as a TBW greater than 125 percent of the IBW. IBW can be estimated by the following formulas and calculator (
         <a class="calc calc_professional" href="/z/d/html/13489.html" rel="external">
          calculator 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IBW, in kg (males) = 50 + (2.3 x inches above 60 inches)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         IBW, in kg (females) = 45.5 + (2.3 x inches above 60 inches)
        </p>
        <p>
        </p>
        <p>
         For underweight patients, use TBW to calculate dose.
        </p>
        <p>
         For patients whose weight is 1 to 1.25 times their IBW, we typically use IBW to calculate dose.
        </p>
        <p>
         For patients with obesity, whose weight is &gt;1.25 times their IBW, use the adjusted body weight (AdjBW) as follows:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         AdjBW, in kg = IBW + [0.4 x (TBW - IBW)]
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H374425388">
         <span class="h2">
          Creatinine clearance estimation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since aminoglycosides are eliminated primarily by glomerular filtration, renal function affects the rate of drug clearance, and thus affects the optimal dosing interval.
        </p>
        <p>
         The creatinine clearance can be estimated from the serum creatinine concentration using the Cockcroft-Gault formula (
         <a class="calc calc_professional" href="/z/d/html/13496.html" rel="external">
          calculator 2
         </a>
         ) [
         <a href="#rid3">
          3
         </a>
         ]. This formula considers the increase in creatinine production with increasing weight and the decline in creatinine production with age. (See
         <a class="medical medical_review" href="/z/d/html/2359.html" rel="external">
          "Assessment of kidney function"
         </a>
         .)
        </p>
        <p>
         Any formula estimating the creatinine clearance from the serum creatinine concentration presupposes that the serum creatinine is a stable value. In patients who develop acute renal failure, for example, the low glomerular filtration rate will cause creatinine to be retained and thus lead to an elevation in the serum creatinine concentration. However, until a stable value is reached, the above formula might overestimate the creatinine clearance. Similarly, during recovery from acute renal failure, the fall in serum creatinine concentration will lag behind the improvement in glomerular filtration rate due to the time required for excretion of the retained creatinine.
        </p>
        <p>
         Additionally, certain disease states or other factors may alter the relationship between the serum creatinine concentration and creatinine clearance. In particular, creatinine production (and therefore the serum creatinine concentration) is reduced in severe liver disease, malnutrition and significant loss of muscle mass (such as quadriplegic, paraplegic, or amputees), possibly resulting in overestimation of the creatinine clearance with the above formula unless there has been an equivalent reduction in body weight.
        </p>
        <p class="headingAnchor" id="H374425859">
         <span class="h2">
          Monitoring for toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The serum creatinine concentration should be monitored at baseline and repeated every one to three days, depending upon the individual circumstances. Monitoring for ototoxicity involves subjective patient assessment for the presence of auditory and vestibular dysfunction. The use of objective testing, such as audiometry or electronystagmography, is generally reserved for patients who have subjective symptoms of ototoxicity, pre-existing auditory dysfunction, or for those receiving prolonged treatment (such as for mycobacterial infections).
        </p>
        <p class="headingAnchor" id="H374424323">
         <span class="h1">
          COMPARING EXTENDED-INTERVAL AND TRADITIONAL INTERMITTENT DOSING
         </span>
         <span class="headingEndMark">
          —
         </span>
         Parenteral aminoglycosides can be administered using a traditional intermittent dosing strategy, which uses smaller doses given two to three times daily (in patients with normal renal function), or an extended-interval dosing strategy, which uses higher doses administered at an extended interval (between 24 and 48 hours).
        </p>
        <p class="headingAnchor" id="H639387843">
         <span class="h2">
          Advantages of extended-interval dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extended-interval aminoglycoside has efficacy comparable with traditional intermittent administration but offers three potential advantages:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Possibility of decreased nephrotoxicity (based on data from animal models) (see
         <a class="local">
          'Nephrotoxicity'
         </a>
         below)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Ease of administration and serum concentration monitoring
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Reductions in administration and monitoring-related costs
        </p>
        <p>
        </p>
        <p>
         Extended-interval dosing of aminoglycosides takes advantage of two pharmacodynamic properties: the post-antibiotic effect and concentration-dependent killing. The post-antibiotic effect refers to the persistent inhibitory effect against many gram-negative aerobic organisms that is seen after drug clearance, and concentration-dependent killing refers to the ability of escalating concentrations of aminoglycosides to induce more rapid killing of the pathogen. These properties are discussed in more detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides", section on 'Post-antibiotic effect'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides", section on 'Concentration-dependent killing'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h2">
          Efficacy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Multiple trials in various adult and pediatric populations evaluating a wide spectrum of infections have demonstrated comparable efficacy of extended-interval dosing with traditional, intermittent dosing aminoglycoside therapy [
         <a href="#rid4">
          4-12
         </a>
         ]. As an example, in one meta-analysis of 13 randomized controlled trials, extended-interval dosing of aminoglycosides resulted in bacteriologic cure (relative rate 1.02, 95% CI 0.99-1.05) and mortality rates (relative risk 0.91, 95% CI 0.63-1.31) that were comparable to those reported for traditional intermittent dosing [
         <a href="#rid4">
          4
         </a>
         ]. Other meta-analyses in adults and children have demonstrated nonsignificant trends toward decreased antibiotic failure with extended-interval versus traditional dosing [
         <a href="#rid5">
          5,7,8,11,12
         </a>
         ].
        </p>
        <p>
         Specific patient populations in which extended-interval dosing (alone or as part of combination antibiotic therapy) has demonstrated favorable efficacy include the following [
         <a href="#rid4">
          4-13
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Immunocompetent, nonpregnant adults and children &gt;3 months of age with:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Complicated urinary tract infections
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Intra-abdominal infections
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Respiratory tract infections
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Gynecologic infections (including pelvic inflammatory disease)
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Soft-tissue infections
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bacteremia
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Females with postpartum endometritis
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Febrile neutropenia patients with malignancy (adults and children)
        </p>
        <p>
        </p>
        <p>
         There are minimal data evaluating extended-interval dosing for central nervous system, bone/joint infections, and ophthalmologic infections.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          Toxicity
         </span>
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h3">
          Nephrotoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Protection against nephrotoxicity is supported primarily by studies in experimental animals, which suggest that the incidence of acute renal failure is diminished with extended-interval aminoglycoside administration [
         <a href="#rid5">
          5
         </a>
         ]. This protective effect is thought to be associated with diminished aminoglycoside accumulation in the renal cortex, suggesting that drug uptake by the proximal tubule is most efficient at low doses [
         <a href="#rid14">
          14
         </a>
         ]. The concept of saturable transport of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         observed in rat models may explain how at higher doses, more of the drug is excreted without undergoing tubular reabsorption and therefore without accumulating in and injuring the tubular cells. Higher peaks for shorter periods and a prolonged period of very low exposure may allow for more efficient handling and excretion [
         <a href="#rid15">
          15
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">
          "Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity"
         </a>
         .)
        </p>
        <p>
         With respect to clinical data, three meta-analyses, the last in children, found the following risk ratios for nephrotoxicity with extended-interval dosing relative to conventional, intermittent dosing:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risk ratio 0.87, 95% CI 0.60-1.26 [
         <a href="#rid4">
          4
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risk ratio 0.74, 95% CI 0.54-1.00 [
         <a href="#rid5">
          5
         </a>
         ]
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Risk ratio 0.97, 95% CI 0.55-1.69 [
         <a href="#rid8">
          8
         </a>
         ]
        </p>
        <p>
        </p>
        <p>
         Thus, in contrast to the animal data, there was no clear evidence of protection against nephrotoxicity with extended-interval dosing in humans. However, there are potentially important limitations to these meta-analyses in adults [
         <a href="#rid4">
          4-7
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The time period covered by the meta-analyses was similar, but the number of trials included for analysis ranged from 13 to 21, indicating differing methodologies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The majority of trials focused on aminoglycosides other than
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         . Each meta-analysis included only two trials of gentamicin, the same two in two of the analyses and an additional one in the third. Only one meta-analysis included a study of tobramycin.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other antibiotics were administered with aminoglycosides in the majority of trials, including at least one in which the known nephrotoxin amphotericin B was included.
        </p>
        <p>
        </p>
        <p>
         Individual studies have attempted to address the nephrotoxic potential of extended-interval dosing. A prospective, randomized, double-blind trial performed after the meta-analyses included 74 patients, almost all of whom were treated with
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         [
         <a href="#rid16">
          16
         </a>
         ]. Extended-interval dosing resulted in less nephrotoxicity than twice daily dosing in patients receiving aminoglycosides for at least 72 hours (0 versus 15 percent). In a multivariate logistic regression analysis, the daily area under plasma concentration-time curve (AUC) and concomitant use of
         <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">
          vancomycin
         </a>
         were significant factors in the development of nephrotoxicity. Experience in patients with cystic fibrosis has also suggested the potential for reduced nephrotoxicity compared with three times daily dosing [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p>
         Data regarding the nephrotoxicity of
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         are limited [
         <a href="#rid18">
          18
         </a>
         ]. Based on data generated from studies in patients with either complicated urinary tract infection or infections caused by carbapenem-resistant Enterobacteriaceae, rates of plazomicin-associated nephrotoxicity (4.8 percent) were not statistically different from the comparator agent.
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h3">
          Ototoxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Meta-analyses and most studies have not demonstrated a clear difference in ototoxicity with the two regimens [
         <a href="#rid4">
          4-8,16,19
         </a>
         ]. In one meta-analysis, for example, the risk ratio for ototoxicity with extended-interval dosing compared with traditional-intermittent dosing was 0.67 (95% CI 0.35-1.28) [
         <a href="#rid4">
          4
         </a>
         ]. In contrast, some observational data have suggested that extended-interval dosing was associated with vestibular toxicity at lower cumulative doses and shorter durations of therapy [
         <a href="#rid20">
          20
         </a>
         ]. Differences in study design (eg, lack of randomization, variable endpoint definitions or detection measurements) and patient populations may account for some of the differences observed. Nevertheless, the presence or possibility of ototoxicity should be more closely monitored with extended-interval therapy because of the higher peak plasma concentrations. In addition, extended-interval dosing is commonly used in patients receiving extended durations of therapy, which may increase the risk. (See
         <a class="medical medical_review" href="/z/d/html/7242.html" rel="external">
          "Pathogenesis and prevention of aminoglycoside nephrotoxicity and ototoxicity", section on 'Ototoxicity'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Convenience and cost
         </span>
         <span class="headingEndMark">
          —
         </span>
         As noted above, other potential advantages of extended-interval aminoglycoside therapy relative to traditional intermittent dosing include ease of administration and reduced preparation and administration times. Published reports have confirmed the ability of extended-interval dosing to reduce the costs associated with therapeutic drug monitoring if the monitoring approach suggested below is followed [
         <a href="#rid21">
          21
         </a>
         ]. (See
         <a class="local">
          'Extended-interval dosing and monitoring'
         </a>
         below.)
        </p>
        <p>
         Furthermore, an extended dosing interval may also help facilitate the transition from inpatient to outpatient care.
        </p>
        <p class="headingAnchor" id="H3416267786">
         <span class="h2">
          Precautions with extended-interval dosing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Extended-interval aminoglycoside dosing represents a deviation from the US Food and Drug Administration (FDA)-approved manufacturer's package insert. Prescribing outside the recommendations of the package insert is not uncommon for aminoglycosides or many other drugs. However, use of extended-interval aminoglycoside therapy also deviates from the "standard of practice" of measuring and documenting serum concentrations within a defined therapeutic range. Peak serum concentrations with extended-interval dosing are considerably higher than those traditionally targeted by some laboratories and may trigger an alert.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h1">
          SELECTION OF DOSING STRATEGY
         </span>
        </p>
        <p class="headingAnchor" id="H4228860972">
         <span class="h2">
          Patients with normal renal function
         </span>
        </p>
        <p class="headingAnchor" id="H3676748648">
         <span class="h3">
          For gram-negative bacterial infection
         </span>
         <span class="headingEndMark">
          —
         </span>
         For most patients receiving aminoglycosides for suspected or documented infection due to gram-negative aerobic bacteria, we suggest extended-interval dosing rather than traditional intermittent dosing. Extended-interval dosing has comparable efficacy and safety with superior pharmacodynamic profiles and greater ease of administration (see
         <a class="local">
          'Comparing extended-interval and traditional intermittent dosing'
         </a>
         above). This approach is consistent with recommendations from the Infectious Diseases Society of America (IDSA) guidelines on the treatment of multidrug-resistant gram-negative infections [
         <a href="#rid22">
          22
         </a>
         ].
        </p>
        <p>
         It is unknown whether extended-interval aminoglycoside dosing is associated with a greater risk of oto- or nephrotoxicity in settings such as the use of concomitant nephrotoxic or ototoxic agents, prolonged courses of therapy, and pre-existing vestibular or hearing loss. Although we do not exclude such patients from receiving extended-interval dosing, we monitor them closely for toxicity during therapy.
        </p>
        <p class="headingAnchor" id="H993995031">
         <span class="h3">
          For gram-positive bacterial infections
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aminoglycosides may be used in combination with other agents to treat specific serious gram-positive bacterial infections (ie, for synergy). In such settings, lower concentrations of aminoglycosides are targeted, whether traditional or extended-interval dosing intervals are used. Selection of dosing regimen depends on the pathogen being treated:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For invasive enterococcal infections (such as endocarditis), traditional intermittent dosing of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         is preferred when the agent is used for synergy because of insufficient data informing clinical outcomes with extended-interval dosing [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For prosthetic valve endocarditis due to
         <em>
          Staphylococcus
         </em>
         species, traditional intermittent dosing of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         is preferred when the agent is used for synergy because of insufficient data informing clinical outcomes with extended-interval dosing [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For endocarditis due to
         <em>
          Streptococcus
         </em>
         species, extended-interval dosing of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         (3 mg/kg/day as a single daily dose) is preferred when the agent is used for synergy [
         <a href="#rid23">
          23,24
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis", section on 'Viridans streptococci and S. bovis/S. equinus complex'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis", section on 'Enterococci'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2523888050">
         <span class="h2">
          Patients with renal impairment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with renal impairment may be more likely to have aminoglycoside toxicity when administered at a high dose, and there has been a paucity of data in this population. Therefore, when aminoglycosides are used in patients with renal impairment (creatinine clearance is less than 40 mL/min), requiring renal replacement therapy, or unstable renal function, we suggest traditional intermittent dosing rather than extended-interval dosing.
        </p>
        <p>
         Although some institutions permit extended-interval dosing for patients with a creatinine clearance as low as 30 mL/min (with the interval extended to 48 hours), we generally advise against this practice.
        </p>
        <p class="headingAnchor" id="H1085578816">
         <span class="h2">
          Patients with augmented renal aminoglycoside clearance
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Identifying patients with augmented renal clearance
         </strong>
         – Augmented renal clearance (ARC) is often defined as a calculated creatinine clearance &gt;130 mL/min using an 8- to 24-hour urine creatinine collection [
         <a href="#rid25">
          25
         </a>
         ]. ARC of aminoglycosides can occur in patients with sepsis, burn injury, trauma, traumatic brain injury, and cystic fibrosis. Associated clinical features may also include age &lt;40 years, higher lean body mass, increased urine output, and normal or low serum creatinine concentration. In addition to these clinical features, one of the best methods for recognizing ARC is identifying those with subtherapeutic serum aminoglycoside concentrations despite adequate dosing.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Identification of patients with ARC based on urine creatine collection is often impractical given the urgent need to initiate treatment in many cases [
         <a href="#rid26">
          26
         </a>
         ]. Common equations used to estimate creatinine clearance (such as the Cockcroft-Gault [CG] equation) may underestimate actual clearance if the estimate is &gt;120 mL/min [
         <a href="#rid27">
          27-29
         </a>
         ]. Alternate methods (including measurement of cystatin C) have been investigated, but most lack the necessary sensitivity and specificity to be clinically useful [
         <a href="#rid26">
          26
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Selection of dosing strategy with ARC
         </strong>
         – Published data are limited to determine the optimal method of initial aminoglycoside dosing in the setting of ARC, particularly in adults. As a result, clinical practice varies between traditional intermittent dosing, and extended-interval dosing. Regardless of dosing method used, we recommend early and frequent monitoring of drug concentrations with pharmacist assistance to inform dosing adjustments. We recommend against nomogram-based dosing in patients with ARC.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         As in other populations, a potential benefit of extended-interval dosing is that it takes advantage of the pharmacokinetics/pharmacodynamics to optimize the ratio of the peak concentration or the area under the curve to the minimum inhibitory concentration (Cmax/MIC or AUC/MIC) by using higher doses less frequently. This may also minimize toxicity with increased drug-free time compared with traditional intermittent dosing. The potential risks of undertreatment with excess drug-free time are generally mitigated by the other antibiotics used in combination with aminoglycosides.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         For pathogens that have a MIC of ≥2 to
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         (as seen in many multidrug-resistant gram-negative bacteria), an optimal Cmax/MIC or AUC/MIC may not be achievable, even with an extended-interval dosing approach [
         <a href="#rid30">
          30-32
         </a>
         ]. In such cases, antibiotics other than aminoglycosides should be used.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to extended-interval dosing with ARC
         </strong>
         – When treating invasive gram-negative bacterial infections in patients with ARC, aminoglycoside dosing should also consider the high volumes of distribution often observed in patients with critical illness. A reasonable modification to an extended-interval dosing approach in the setting of ARC is to:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use an initial dose of at least 7 mg/kg for
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         or 15 to 20 mg/kg for
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         These doses generally achieve pharmacodynamic targets for aminoglycosides for susceptible pathogens (MIC &lt;0.5 mcg/mL) in critically ill patients [
         <a href="#rid30">
          30
         </a>
         ]. Some sources recommend higher initial dosing (eg, 8 to 10 mg/kg for
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         and 20 mg/kg for
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         ) to increase the probability of achieving pharmacodynamic targets for pathogens with higher MICs (but still &lt;1 mcg/mL) and/or for patient populations with higher volumes of distribution [
         <a href="#rid30">
          30
         </a>
         ]. However, routine use of higher initial doses is generally reserved for populations for whom increased clearance is most predictable (such as in patients with cystic fibrosis). (See
         <a class="local">
          'Cystic fibrosis'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Obtain two serum aminoglycoside concentrations:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The first concentration should be obtained approximately one to two hours after the initial dose (to allow for drug distribution). This concentration should be used to extrapolate a true peak concentration (Cmax).
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         The second concentration should optimally be obtained at least one half-life following the initial measurement but still allow sufficient time to determine dose requirements prior to the next scheduled dose. This is usually within 12 to 18 hours after administration.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Based on serum concentration results and pharmacokinetic calculations, adjust the adjusted dose and dosing interval to target:
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A goal peak concentration of 15 to 20 mcg/mL for
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         or 35 to 50 mcg/mL for
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         .
        </p>
        <p>
        </p>
        <p class="bulletIndent3">
         <span class="glyph">
          -
         </span>
         A goal trough concentration of &lt;0.25 mcg/mL (below the limit of detection) for
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         or &lt;4 mcg/mL for
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         for &gt;4 hours prior to redosing.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Reassess the aminoglycoside concentrations early and frequently. Given the significant variation in the duration of ARC [
         <a href="#rid29">
          29
         </a>
         ], this is important to optimize both efficacy and safety. In patients with stable renal function and dosing, monitoring should be repeated at least weekly if therapy will be prolonged beyond 7 to 10 days.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Approach to traditional intermittent dosing with ARC
         </strong>
         – The approach is the same as that used in patients without ARC and is discussed elsewhere. (See
         <a class="local">
          'Traditional dosing and monitoring'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H538445773">
         <span class="h1">
          GENTAMICIN AND TOBRAMYCIN DOSING IN ADULTS
         </span>
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h2">
          Extended-interval dosing and monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Administration of a higher dose of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         at an extended interval is dependent on renal function and subsequent monitoring of serum drug concentrations. Below is the method we use in adults.
        </p>
        <p>
         Calculation of dosing weight and creatinine clearance, both of which are important for dose and dosing interval determination, are discussed above. (See
         <a class="local">
          'Dosing weight'
         </a>
         above and
         <a class="local">
          'Creatinine clearance estimation'
         </a>
         above.)
        </p>
        <p>
         Dosing for children and other specific populations are discussed elsewhere. (See
         <a class="local">
          'Dosing for special circumstances'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H374425912">
         <span class="h3">
          Initial dose and dosing interval
         </span>
         <span class="headingEndMark">
          —
         </span>
         A loading dose is not needed in the setting of extended-interval aminoglycoside administration. At our institution, we use an initial
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         dose of 7 mg/kg and determine the interval based on serum concentration plotted on a nomogram. We use the nomogram developed at Hartford Hospital, the most widely used nomogram in the United States  (
         <a class="graphic graphic_figure graphicRef62508" href="/z/d/graphic/62508.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid33">
          33
         </a>
         ]. An alternative is to use more intensive monitoring to determine the appropriate dosing interval based on target concentrations. (See
         <a class="local">
          'Intensive monitoring'
         </a>
         below and
         <a class="local">
          'Target concentrations'
         </a>
         below.)
        </p>
        <p>
         While some institutions use lower initial doses (ie,
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         5 mg/kg) for either all or selected patients (such as postpartum individuals with endometritis), these lower doses may be most appropriate for settings in which the pathogen is highly susceptible. Use of nomograms to adjust doses may also be unreliable with such doses. Since our use of aminoglycosides is generally reserved for patients with serious, invasive illness in whom decreased susceptibility is more likely, with the exception of postpartum endometritis, we favor 7 mg/kg dose for most patients.
        </p>
        <p>
         The 5 mg/kg dose of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         is also used for selected cases of urinary tract infection; this is discussed in detail elsewhere. [
         <a href="#rid34">
          34
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/16109.html" rel="external">
          "Acute complicated urinary tract infection (including pyelonephritis) in adults and adolescents", section on 'Outpatients'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Drug concentration monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         When an extended-interval daily dosing strategy is employed, the timing and frequency of serum drug concentration monitoring differ from those used in traditional dosing. Concentrations can be targeted either by using a published nomogram that extrapolates desired dosing interval based on a single drug concentration (see
         <a class="local">
          'Nomogram-based monitoring'
         </a>
         below) or by analysis of two or more serum concentrations checked during the dosing cycle (see
         <a class="local">
          'Intensive monitoring'
         </a>
         below). The latter (intensive monitoring) is generally employed when extended-interval dosing is used in special populations that may have unpredictable pharmacokinetics, such as patients with burns, ascites, and critical illness. (See
         <a class="local">
          'Dosing for special circumstances'
         </a>
         below.)
        </p>
        <p>
         When the course of extended-interval aminoglycosides is not expected to exceed three daily doses (eg, for most cases of postpartum endometritis), serum drug concentration monitoring is likely unnecessary in patients with normal renal function. Even in such cases, monitoring of renal function is still warranted in order to reflect potential drug-related nephrotoxicity and to signal a change in drug elimination. Drug concentration measurements should be repeated with a change in renal function and when duration of therapy exceeds 7 to 10 days. Although most manufacturers recommend measuring aminoglycoside concentrations throughout the course of therapy, such recommendations are based upon traditional intermittent dosing strategies and may not apply to extended-interval dosing.
        </p>
        <p>
         Regardless of the method used to determine patient dosing needs, sampling times must be documented by the phlebotomist for accurate interpretation of results. In addition, requests for laboratory determinations of serum concentrations should include a provision to indicate that extended-interval dosing is being utilized. Since serum concentrations obtained (especially the peak concentrations) will be substantially different from those obtained with traditional intermittent dosing, clinicians, pharmacists, and laboratory personnel need to know the dosing method for appropriate interpretation.
        </p>
        <p class="headingAnchor" id="H729370348">
         <span class="h4">
          Target concentrations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although peak and trough concentrations are not directly measured for extended-interval dosing, serum concentrations obtained within specified intervals during the dosing cycle are used to extrapolate and adjust dosing to achieve intended targets. Extended-interval aminoglycoside dosing targets a peak serum concentration of approximately 15 to 20 mcg/mL for
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         in order to target approximately 10 times the MIC of the pathogen [
         <a href="#rid35">
          35
         </a>
         ]. Trough serum concentrations should be less than 1 mcg/mL (are most often undetectable) because of the extended dosing interval. The estimated drug-free interval (ie, concentration is undetectable) is less than eight hours.
        </p>
        <p class="headingAnchor" id="H538446039">
         <span class="h4">
          Nomogram-based monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Application of the published nomogram requires that a single serum concentration be obtained 6 to 14 hours after the first dose  (
         <a class="graphic graphic_figure graphicRef62508" href="/z/d/graphic/62508.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid21">
          21
         </a>
         ]. Results from this measurement are then used to determine the necessary dosing interval. Successful application of this approach has been documented [
         <a href="#rid33">
          33
         </a>
         ].
        </p>
        <p>
         Although unlikely to result in peak serum concentrations below the desired target value when doses of 7 mg/kg are employed, single-concentration serum monitoring requires assumptions that individual patients exhibit kinetic parameters comparable to other patients. Patients not conforming to usual population kinetic parameters may have suboptimal serum aminoglycoside concentrations if doses are calculated from the standard nomogram. Appropriate patient selection should significantly reduce the risk of such variability.
        </p>
        <p class="headingAnchor" id="H538446062">
         <span class="h4">
          Intensive monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         An alternative to the use of the nomogram is to obtain a peak serum aminoglycoside concentration (60 minutes post-infusion) and a second concentration approximately 6 to 12 hours after the first or second dose. Dosing adjustment based on these concentrations is generally performed with the assistance of a clinical pharmacist based on individualized patient pharmacokinetic parameters.
        </p>
        <p>
         Additional samples may be obtained during the course of therapy (eg, sample 6 to 12 hours post-infusion after the same dose) to verify that concentrations have not changed significantly. The disadvantage to this method is the requirement of more sophisticated analyses (usually performed by pharmacists).
        </p>
        <p class="headingAnchor" id="H987137334">
         <span class="h2">
          Traditional dosing and monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Traditional, intermittent dosing involves administration of a loading dose, administration of a maintenance dose at a specific interval (depending on renal function), and subsequent monitoring of serum concentrations of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         to guide dose adjustments. Below is a step-by-step method used for dosing gentamicin and tobramycin in adults. This differs slightly from manufacturer recommendations, since dosing according to the package insert consistently resulted in suboptimal peak serum concentrations at our institution. Recommendations from the manufacturer can be obtained by reviewing the package insert [
         <a href="#rid36">
          36,37
         </a>
         ].
        </p>
        <p>
         Determination of dosing weight and estimation of creatinine clearance, both of which are important for dose and dosing interval determination, are discussed above. (See
         <a class="local">
          'Dosing weight'
         </a>
         above and
         <a class="local">
          'Creatinine clearance estimation'
         </a>
         above.)
        </p>
        <p>
         Dosing for children, burn patients, patients on dialysis, and other specific populations are discussed elsewhere. (See
         <a class="local">
          'Dosing for special circumstances'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H3303635559">
         <span class="h3">
          Loading dose
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial loading dose is determined by type or site of infection, for which different peak serum
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         concentrations are desired  (
         <a class="graphic graphic_table graphicRef79468" href="/z/d/graphic/79468.html" rel="external">
          table 1
         </a>
         ). In general, loading doses for gram-negative infections are generally 2.5 to 3 mg/kg dosing weight. Higher loading doses are used for pneumonia or acute life-threatening gram-negative infections than for acute simple cystitis (eg, uncomplicated lower urinary tract infections) because of the lower serum drug concentrations required to successfully treat cystitis. In the setting of synergy for gram-positive infections, loading doses are not employed.
        </p>
        <p class="headingAnchor" id="H2517576759">
         <span class="h3">
          Initial maintenance dose and dosing interval
         </span>
         <span class="headingEndMark">
          —
         </span>
         For maintenance dosing, a specific percentage of the loading dose is given at a specific dosing interval, both of which depend on the creatinine clearance, an estimate of glomerular filtration rate  (
         <a class="graphic graphic_table graphicRef57375" href="/z/d/graphic/57375.html" rel="external">
          table 2
         </a>
         ). In those patients in whom a loading dose was not given, the maintenance dose is still determined by the estimated loading dose  (
         <a class="graphic graphic_table graphicRef79468" href="/z/d/graphic/79468.html" rel="external">
          table 1
         </a>
         ) for the indication. For adults with normal renal function who have serious gram-negative infections, the maintenance dose of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         is generally 2 mg/kg every eight hours.
        </p>
        <p>
         In order to meet the desired target concentrations, both the maintenance dose and the dosing interval may need to be adjusted based on the results of drug concentration monitoring, as below.
        </p>
        <p class="headingAnchor" id="H3317359727">
         <span class="h3">
          Drug concentration monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Monitoring of serum aminoglycoside concentrations is essential to ensure efficacy and to avoid toxicity. Routine measurement of serum aminoglycoside concentrations is not necessary with prophylactic therapy given for less than 24 hours.
        </p>
        <p class="headingAnchor" id="H1265045130">
         <span class="h4">
          Timing
         </span>
         <span class="headingEndMark">
          —
         </span>
         Serum concentrations should be determined when the patient has received therapy for three to five half-lives of the drug (typically around two to three maintenance doses or after adjustment of the dose). Two or more concentrations measured after the first dose may be useful for patients who are unlikely to exhibit predictable kinetics (such as those with unstable renal function or extremes of age or weight) or in whom routine monitoring would otherwise be significantly delayed due to a prolonged half-life from renal dysfunction.
        </p>
        <p>
         Trough concentrations are measured within 30 minutes prior to the next dose and peak concentrations 30 to 45 minutes after the end of an intravenous infusion or approximately 60 minutes after an intramuscular injection. An accurate record of aminoglycoside administration times and the time the samples are obtained is essential in interpreting the results. Thus, sample times should be documented on the laboratory requisition. Drug administration records should be checked to verify that doses have been administered as scheduled.
        </p>
        <p class="headingAnchor" id="H3451802121">
         <span class="h4">
          "Target" concentrations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Desired peak concentrations for
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         are dependent upon the indication and site of infection  (
         <a class="graphic graphic_table graphicRef79468" href="/z/d/graphic/79468.html" rel="external">
          table 1
         </a>
         ):
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         is given for synergy of infections outside the central nervous system (eg, for certain gram-positive infections), the target peak concentration is 3 to 4 mcg/mL. Higher target peak concentrations are sometimes used for certain gram-positive central nervous system infections in an attempt to achieve concentrations at the site of infection that are adequate for synergy, but the optimal serum peak concentrations for this are uncertain.
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          Tobramycin
         </a>
         is not administered for synergy.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         When
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         is given for the treatment of serious, invasive infections (including gram-negative pneumonia or critical illness due to gram-negative infection), target peak concentrations are 7 to 10 mcg/mL. Higher peak serum concentrations (up to 12 mcg/mL, depending on susceptibility of the organism) have been targeted for treatment of pulmonary infections in patients with cystic fibrosis. A maximum concentration (Cmax)/minimum inhibitory concentration (MIC) ratio of at least 4.5 may correspond to a better clinical outcome [
         <a href="#rid38">
          38
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Trough concentrations for
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         should be below 2 mcg/mL. Many pharmacists will target a trough concentration of &lt;1 mcg/mL when estimating dose and frequency to avoid excessive trough concentrations in settings where population kinetic parameters are less predictable.
        </p>
        <p class="headingAnchor" id="H800423666">
         <span class="h3">
          Dosing adjustments
         </span>
         <span class="headingEndMark">
          —
         </span>
         In general, changes in the dose (while keeping the frequency fixed) will result in proportional changes in both peak and trough concentration values. As an example, a 25 percent dosage increase will result in a 25 percent increase in both peak and trough steady-state serum concentrations.
        </p>
        <p>
         Changes in the dosing interval while keeping the dose constant will also result in similar directional changes to both peak and trough, although such changes are not proportional. Therefore, calculation of patient-specific pharmacokinetic parameters (most frequently performed by institution-based pharmacists) is the optimal method to determine needed dose and frequency modification based on serum concentration values.
        </p>
        <p class="headingAnchor" id="H2503310158">
         <span class="h3">
          Frequency of monitoring
         </span>
         <span class="headingEndMark">
          —
         </span>
         Once the desired peak and trough serum concentrations are achieved, serum aminoglycoside concentrations should be re-evaluated throughout therapy when there are any changes in renal function. The need for repeated serum concentration monitoring once desired concentrations are achieved in patients with stable renal function is less clear. However, monitoring should be repeated at least weekly if therapy will be prolonged beyond 7 to 10 days.
        </p>
        <p class="headingAnchor" id="H324632593">
         <span class="h1">
          DOSING OF OTHER AMINOGLYCOSIDES IN ADULTS
         </span>
        </p>
        <p class="headingAnchor" id="H374425111">
         <span class="h2">
          Amikacin
         </span>
         <span class="headingEndMark">
          —
         </span>
         Target serum concentration for traditional dosing of
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         are a peak of 20 to 30 mcg/mL and a trough of &lt;8 mcg/mL (often targeted at 1 to 4 mcg/mL). Higher peak concentrations (up to 40 mcg/mL) are often recommended for serious, life-threatening infections such as nosocomial pneumonia. Higher peaks (40 to 50 mcg/mL) are generally achieved with extended-interval dosing.
        </p>
        <p>
         For patients receiving traditional dosing of
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         , the usual loading dose is 7.5 mg/kg, with a subsequent maintenance dose of 15 mg/kg per day. The maintenance dose is typically given in divided doses every 8 to 12 hours for patients with normal renal function. Similar to
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         , adjustments in the frequency of administration should be made for reductions in renal function  (
         <a class="graphic graphic_table graphicRef57375" href="/z/d/graphic/57375.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         For patients receiving extended-interval dosing of
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         , a 15 mg/kg dose is administered. Subsequent drug concentration monitoring and dosing interval determination are similar to those for
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         (ie, making dose and interval adjustments using a nomogram  (
         <a class="graphic graphic_figure graphicRef62508" href="/z/d/graphic/62508.html" rel="external">
          figure 1
         </a>
         ) or more intensive monitoring to target concentrations). However, since the Hartford nomogram was not designed for amikacin, the random serum amikacin concentration should be divided by two if using the nomogram to determine the dosing frequency. (See
         <a class="local">
          'Nomogram-based monitoring'
         </a>
         above and
         <a class="local">
          'Intensive monitoring'
         </a>
         above.)
        </p>
        <p class="headingAnchor" id="H729371441">
         <span class="h2">
          Streptomycin
         </span>
         <span class="headingEndMark">
          —
         </span>
         The dosing of
         <a class="drug drug_general" data-topicid="10238" href="/z/d/drug information/10238.html" rel="external">
          streptomycin
         </a>
         is based on the indications for its use and is discussed elsewhere:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2152.html" rel="external">
          "Antimicrobial therapy of left-sided native valve endocarditis", section on 'Enterococci'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/5341.html" rel="external">
          "Treatment of
          <i>
           Mycobacterium avium
          </i>
          complex pulmonary infection in adults", section on 'Regimen selection'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3141.html" rel="external">
          "Tularemia: Clinical manifestations, diagnosis, treatment, and prevention", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/3131.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of plague (
          <i>
           Yersinia pestis
          </i>
          infection)", section on 'Treatment'
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The drug is approved for intramuscular administration. Intravenous use is not recommended but has been described in the medical literature [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H4035742295">
         <span class="h2">
          Plazomicin
         </span>
         <span class="headingEndMark">
          —
         </span>
         For complicated urinary tract infection,
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         is administered as a 15 mg/kg intravenous dose every 24 hours in adult patients with a creatinine clearance ≥60 mL/min. For patients with a creatinine clearance &lt;60 and ≥30 mL/min, the dose is 10 mg/kg every 24 hours, and for patients with a creatinine clearance &lt;30 and ≥15 mL/min, the dose is 10 mg/kg every 48 hours [
         <a href="#rid40">
          40
         </a>
         ].
        </p>
        <p>
         For all patients with moderate to severe renal impairment (ie, a creatinine clearance &lt;90 and ≥15 mL/min) expected to receive therapy beyond five days, measurement of a
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         trough concentration within 30 minutes prior to the second or third dose is recommended. The dosing interval should be extended when the trough concentration exceeds 3 mcg/mL.
        </p>
        <p>
         Data are lacking to determine optimal
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         dosing for infections outside the urinary tract.
        </p>
        <p>
         While both the dose and frequency of
         <a class="drug drug_general" data-topicid="118322" href="/z/d/drug information/118322.html" rel="external">
          plazomicin
         </a>
         administration are adjusted in patients with renal impairment, such administration is not considered part of the extended-interval dosing strategy. However, application of the Hartford Hospital Aminoglycoside Dosing nomogram has been proposed as a method to dose plazomicin in the setting of invasive gram-negative infections [
         <a href="#rid41">
          41
         </a>
         ] and urinary tract infections [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H374424683">
         <span class="h1">
          DOSING FOR SPECIAL CIRCUMSTANCES
         </span>
         <span class="headingEndMark">
          —
         </span>
         Dose adjustments need to be made in a variety of special populations.
        </p>
        <p class="headingAnchor" id="H374424747">
         <span class="h2">
          Neonates and children
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial dosing and administration of aminoglycosides for neonates and children vary from that in adults and should be based upon age.
        </p>
        <p>
         For traditional intermittent dosing strategies, target drug concentrations are the same as those for adults. Studies in neonates suggest that a loading dose of 2.5 mg/kg of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         may not be sufficient to obtain therapeutic peak concentrations [
         <a href="#rid43">
          43
         </a>
         ], and loading doses of 4 to 5 mg/kg may thus be required. Subsequently, neonates should receive 3.5 to 4 mg/kg per day of gentamicin or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         depending on gestation age, day of life, and renal function. Infants and children older than three months should receive 5 to 7.5 mg/kg per day in divided doses.
        </p>
        <p>
         Studies regarding the use of extended-interval dosing of aminoglycosides in children are somewhat limited. Use of extended-interval dosing is generally not recommended in children younger than three months of age because of decreases in drug clearance at this age. For children older than three months, extended-interval dosing requirements may be age-dependent. In one report of non-critical care, non-cystic fibrosis patients, the following age-related recommendations were made for the initial maintenance dose of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         given once daily: 9.5 mg/kg for those three months to less than two years old, 8.5 mg/kg for those two years to less than eight years old, and 7 mg/kg for those 8 to 18 years old [
         <a href="#rid44">
          44
         </a>
         ]. Most information of pediatric use of extended-interval aminoglycoside dosing is from cystic fibrosis patients; however, further increased doses may be required in this patient population given increases in volume of distribution and elimination.
        </p>
        <p>
         In all cases, appropriate serum concentration monitoring should be performed.
        </p>
        <p class="headingAnchor" id="H1486127962">
         <span class="h2">
          Pregnant women
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aminoglycosides are not commonly used in pregnant women because of concerns for fetal safety and altered pharmacokinetics (primarily enhanced drug clearance). The majority of published data in this population is with "traditional" (ie intermittent) dosing. The primary use of aminoglycosides during pregnancy is during the intrapartum period in the setting of intra-amniotic infection. Dosing for this indication is discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/6762.html" rel="external">
          "Clinical chorioamnionitis", section on 'Antibiotic therapy'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H431489990">
         <span class="h2">
          Renal replacement therapy
         </span>
        </p>
        <p class="headingAnchor" id="H439274062">
         <span class="h3">
          Peritoneal dialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Aminoglycosides are sometimes administered intraperitoneally to treat peritonitis related to peritoneal dialysis. The use and dosing of aminoglycosides in this setting are discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/1882.html" rel="external">
          "Microbiology and therapy of peritonitis in peritoneal dialysis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H374424753">
         <span class="h3">
          Intermittent hemodialysis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Intermittent hemodialysis can decrease pre-dialysis concentrations by 50 percent. Therefore, patients undergoing intermittent hemodialysis generally require supplemental doses of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         of 1 to 2 mg/kg after each dialysis (depending on the time lapsed after the first dose and characteristics of the dialysis delivered) [
         <a href="#rid45">
          45,46
         </a>
         ]. The post-dialysis dose may best be predicted based on pre-dialysis concentrations. Large variability of kinetic parameters within this population generally necessitates more intensive serum concentration monitoring to achieve target concentrations. This is particularly true when comparing patients with acute versus chronic renal failure and can be dependent on the properties of the hemodialysis sessions (eg, flow rate and membrane type). Assessment of post-dialysis concentrations should allow for redistribution of drug back into the blood and therefore ideally be delayed until up to four hours post-dialysis.
        </p>
        <p class="headingAnchor" id="H374424759">
         <span class="h3">
          Continuous AV hemofiltration
         </span>
         <span class="headingEndMark">
          —
         </span>
         Similar to that observed in patients with intermittent hemodialysis, significant inter-patient variability exists among patients undergoing continuous arteriovenous (AV) hemofiltration. Empiric initial daily
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         doses of 2.5 mg/kg administered once daily should be followed by serum concentration monitoring to assure adequate peak and trough concentrations. Alternate dosing regimens at higher dose 6 mg/kg every other day have been explored for sustained low-efficiency dialysis with careful patient monitoring [
         <a href="#rid47">
          47
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H374424765">
         <span class="h2">
          Cystic fibrosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Both the volume of distribution and clearance of aminoglycosides are greatly increased in patients with cystic fibrosis, necessitating higher starting doses (with both intermittent and extended-interval dosing) to achieve target serum concentrations. Initial doses for extended-interval dosing are 10 mg/kg for
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         or
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         and 25 mg/kg for
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          amikacin
         </a>
         ; these doses are generally limited to patients with creatinine clearance &gt;70 mL/min.
        </p>
        <p>
         In addition, since renal clearance may be more challenging to estimate in this patient population, early determination of drug elimination (through use of repeated serum concentration monitoring following the initial dose for patients receiving extended-interval dosing) is advised in patients for whom prior dosing requirements have not been determined. Aminoglycoside dosing in cystic fibrosis patients is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/140721.html" rel="external">
          "Cystic fibrosis: Antibiotic therapy for pulmonary exacerbations", section on 'Aminoglycosides'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H374424771">
         <span class="h2">
          Burn patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with significant burns may exhibit larger volumes of distribution when compared with most patient populations. As a result, maintenance doses of
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         and
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
         of up to 7 to 8 mg/kg per day (in divided doses) may be needed to attain therapeutic serum aminoglycoside concentrations. Serum concentration monitoring and individualized dosing correlates with survival in this patient population [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2080838609">
         <span class="h2">
          Critical illness (including sepsis)
         </span>
         <span class="headingEndMark">
          —
         </span>
         Septic patients undergoing aggressive fluid resuscitation in the setting of resolving or evolving acute renal failure often warrant especially close monitoring. Critically ill patients may need higher doses to obtain targeted concentrations [
         <a href="#rid48">
          48
         </a>
         ]. Some suggest individualized, intensive monitoring for such patients [
         <a href="#rid49">
          49
         </a>
         ] (see
         <a class="local">
          'Intensive monitoring'
         </a>
         above). Peak concentrations of aminoglycosides may be affected by high volumes of intravenous fluids or extravascular fluid shifts, requiring adjustments in determination of pharmacokinetic parameters (such as volume of distribution).
        </p>
        <p class="headingAnchor" id="H374424777">
         <span class="h2">
          Older adult patients
         </span>
         <span class="headingEndMark">
          —
         </span>
         Since many older adult patients have reduced renal function and/or are receiving concomitant nephrotoxic agents, caution should be used in prescribing aminoglycosides in this patient population. Reduced muscle mass and the resulting reductions in serum creatinine concentration in older adults may result in overestimation of renal function when formulas such as the Cockcroft-Gault equation are utilized. Therefore, a relatively normal serum creatinine may be associated with a substantial loss of renal function in this patient population. A creatinine increase greater than 50 percent over baseline requires careful evaluation of urine output and urinalysis for evidence of drug-induced nephrotoxicity.
        </p>
        <p class="headingAnchor" id="H1555888616">
         <span class="h2">
          Class 2 or greater obesity
         </span>
         <span class="headingEndMark">
          —
         </span>
         The impact of obesity on estimations of renal function is discussed elsewhere (see
         <a class="medical medical_review" href="/z/d/html/2378.html" rel="external">
          "Calculation of the creatinine clearance"
         </a>
         ). In addition, determination of an adjusted body weight, as discussed above (see
         <a class="local">
          'Dosing weight'
         </a>
         above), is necessary to recognize the partial distribution of aminoglycosides into adipose tissue.
        </p>
        <p class="headingAnchor" id="H26719697">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing weight and renal function
         </strong>
         –
         <strong>
         </strong>
         The first steps in aminoglycoside administration include determination of the dosing weight and estimation of renal function. Calculation of the dosing weight differs between patients who are underweight, average weight, and with obesity. (See
         <a class="local">
          'General principles'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing options
         </strong>
         – Parenteral aminoglycosides can be administered using a traditional intermittent dosing strategy, which uses smaller doses given several times each day, or an extended-interval dosing strategy, which uses high doses administered at an extended interval. These two strategies have comparable efficacy and safety. High dose extended-interval administration takes advantage of the pharmacodynamic properties of aminoglycosides and offers greater ease of preparation, administration, and monitoring. (See
         <a class="local">
          'Comparing extended-interval and traditional intermittent dosing'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preference for extended-interval dosing
         </strong>
         – For most patients receiving an aminoglycoside for suspected or documented gram-negative aerobic bacterial infection, we suggest extended-interval rather than traditional intermittent dosing (
         <a class="grade" href="https:///uptodate/show/grade_5" rel="external">
          Grade 2B
         </a>
         ). We avoid extended-interval dosing in patients with creatinine clearance &lt;30 mL/min (including patients requiring dialysis) because of the potentially greater risk of toxicity with higher doses. (See
         <a class="local">
          'Selection of dosing strategy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Patients who have augmented renal clearance (eg, some patients with burns, critical illness, trauma) have altered aminoglycoside pharmacokinetics that could render extended-interval dosing less reliable. If extended-interval dosing is used for such patients, individualized monitoring with pharmacist assistance should be used to determine dose adjustments rather than nomogram-based monitoring. (See
         <a class="local">
          'Patients with augmented renal aminoglycoside clearance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Dosing of
         </strong>
         <a class="drug drug_general" data-topicid="8489" href="/z/d/drug information/8489.html" rel="external">
          gentamicin
         </a>
         <strong>
          or
         </strong>
         <a class="drug drug_general" data-topicid="10000" href="/z/d/drug information/10000.html" rel="external">
          tobramycin
         </a>
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extended-interval dosing
         </strong>
         – This involves administration of a higher dose (we use 7 mg/kg) administered at an extended interval. Extended-interval dosing targets a peak serum concentration of 15 to 20 mcg/mL and trough concentrations less than 1 mcg/mL. Dose adjustments can be made using a published nomogram  (
         <a class="graphic graphic_figure graphicRef62508" href="/z/d/graphic/62508.html" rel="external">
          figure 1
         </a>
         ) or through individualized monitoring with the assistance of a pharmacist. For serious, invasive infections (including gram-negative pneumonia or critical illness due to gram-negative infection), target peak concentrations are 7 to 10 mcg/mL; target trough concentrations are at least &lt;2 mcg/mL (many target a trough &lt;1 mcg/mL). (See
         <a class="local">
          'Extended-interval dosing and monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Traditional, intermittent dosing
         </strong>
         – This involves administration of a loading dose based on indication  (
         <a class="graphic graphic_table graphicRef79468" href="/z/d/graphic/79468.html" rel="external">
          table 1
         </a>
         ), administration of a maintenance dose at a specific interval several times daily (depending on renal function)  (
         <a class="graphic graphic_table graphicRef57375" href="/z/d/graphic/57375.html" rel="external">
          table 2
         </a>
         ), and subsequent monitoring of serum concentrations to guide dose adjustments. Our approach to traditional, intermittent dosing differs slightly from manufacturer recommendations, since dosing according to the package insert consistently resulted in suboptimal peak serum concentrations at our institution. (See
         <a class="local">
          'Traditional dosing and monitoring'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8536" href="/z/d/drug information/8536.html" rel="external">
          Amikacin
         </a>
         <strong>
          dosing
         </strong>
         – Target serum concentration for amikacin are a peak of 20 to 30 mcg/mL and a trough of at least &lt;8 mcg/mL (often targeted at 1 to 4 mcg/mL). Higher peak concentrations (up to 40 mcg/mL) are often recommended for serious, life-threatening infections. For patients receiving traditional dosing of amikacin, the usual loading dose is 7.5 mg/kg, with a subsequent maintenance dose of 15 mg/kg per day in two or three divided doses. For patients receiving extended-interval dosing of amikacin, a 15 mg/kg dose is administered, with subsequent dosing determined by a nomogram  (
         <a class="graphic graphic_figure graphicRef62508" href="/z/d/graphic/62508.html" rel="external">
          figure 1
         </a>
         ) or more intensive monitoring to target concentrations. (See
         <a class="local">
          'Amikacin'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Special circumstances warranting dosing adjustments
         </strong>
         – Dosing adjustments are indicated in certain populations, including children, patients on dialysis, burn patients, and older adults. Septic patients undergoing aggressive fluid resuscitation in the setting of resolving or evolving acute renal failure often warrant especially close monitoring. (See
         <a class="local">
          'Dosing for special circumstances'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Aminoglycosides generally used in combination
         </strong>
         – For serious infections due to typical gram-negative bacteria, with the exception of urinary tract infections, aminoglycosides are generally used in combination with other agents that have gram-negative activity, regardless of dosing method. (See
         <a class="medical medical_review" href="/z/d/html/483.html" rel="external">
          "Aminoglycosides", section on 'Clinical use'
         </a>
         .)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li class="breakAll">
          Achaogen. Antimicrobial Drugs Advisory Committee Meeting Briefing Book: Plazomicin. May 2, 2018. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM606040.pdf (Accessed on July 18, 2018).
         </li>
         <li class="breakAll">
          Trissel LA. Handbook on Injectable Drugs, 14th Ed, American Society of Health-System Pharmacists, Bethesda 2007.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gault MH, Longerich LL, Harnett JD, Wesolowski C. Predicting glomerular function from adjusted serum creatinine. Nephron 1992; 62:249.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hatala R, Dinh T, Cook DJ. Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis. Ann Intern Med 1996; 124:717.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Barza M, Ioannidis JP, Cappelleri JC, Lau J. Single or multiple daily doses of aminoglycosides: a meta-analysis. BMJ 1996; 312:338.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferriols-Lisart R, Alós-Almiñana M. Effectiveness and safety of once-daily aminoglycosides: a meta-analysis. Am J Health Syst Pharm 1996; 53:1141.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Munckhof WJ, Grayson ML, Turnidge JD. A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses. J Antimicrob Chemother 1996; 37:645.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Contopoulos-Ioannidis DG, Giotis ND, Baliatsa DV, Ioannidis JP. Extended-interval aminoglycoside administration for children: a meta-analysis. Pediatrics 2004; 114:e111.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao SC, Ahmed M, Hagan R. One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates. Cochrane Database Syst Rev 2006; :CD005091.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smyth AR, Bhatt J. Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis. Cochrane Database Syst Rev 2012; :CD002009.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           French LM, Smaill FM. Antibiotic regimens for endometritis after delivery. Cochrane Database Syst Rev 2004; :CD001067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mavros MN, Polyzos KA, Rafailidis PI, Falagas ME. Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis. J Antimicrob Chemother 2011; 66:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gilbert DN, Lee BL, Dworkin RJ, et al. A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. Am J Med 1998; 105:182.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giuliano RA, Verpooten GA, De Broe ME. The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats. Am J Kidney Dis 1986; 8:297.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Giuliano RA, Verpooten GA, Verbist L, et al. In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats. J Pharmacol Exp Ther 1986; 236:470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rybak MJ, Abate BJ, Kang SL, et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43:1549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smyth A, Tan KH, Hyman-Taylor P, et al. Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial. Lancet 2005; 365:573.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tang HJ, Lai CC. Plazomicin-associated Nephrotoxicity. Clin Infect Dis 2020; 71:1130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mulheran M, Hyman-Taylor P, Tan KH, et al. Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients. Antimicrob Agents Chemother 2006; 50:2293.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fu TS, Carr SD, Douglas-Jones P, et al. Gentamicin Vestibulotoxicity: Further Insights From a Large Clinical Series. Otol Neurotol 2020; 41:e864.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolau DP, Wu AH, Finocchiaro S, et al. Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring. Ther Drug Monit 1996; 18:263.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa). Clin Infect Dis 2021; 72:e169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baddour LM, Wilson WR, Bayer AS, et al. Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association. Circulation 2015; 132:1435.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sexton DJ, Tenenbaum MJ, Wilson WR, et al. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. Clin Infect Dis 1998; 27:1470.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bilbao-Meseguer I, Rodríguez-Gascón A, Barrasa H, et al. Augmented Renal Clearance in Critically Ill Patients: A Systematic Review. Clin Pharmacokinet 2018; 57:1107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cook AM, Hatton-Kolpek J. Augmented Renal Clearance. Pharmacotherapy 2019; 39:346.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Avedissian SN, Rohani R, Bradley J, et al. Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches. Antimicrob Agents Chemother 2021; 65.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baptista JP, Udy AA, Sousa E, et al. A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance. Crit Care 2011; 15:R139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mikami R, Hayakawa M, Imai S, et al. Onset timing and duration of augmented renal clearance in a mixed intensive care unit. J Intensive Care 2023; 11:13.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Abbasi MY, Chaijamorn W, Wiwattanawongsa K, et al. Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach. Clin Pharmacol 2023; 15:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sader HS, Mendes RE, Kimbrough JH, et al. Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers. Open Forum Infect Dis 2023; 10:ofad058.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xie F, Wang Y, Peng Y, et al. Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit. J Antimicrob Chemother 2021; 76:2335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nicolau DP, Freeman CD, Belliveau PP, et al. Experience with a once-daily aminoglycoside program administered to 2,184 adult patients. Antimicrob Agents Chemother 1995; 39:650.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Goodlet KJ, Benhalima FZ, Nailor MD. A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy? Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karlowsky JA, Zhanel GG, Davidson RJ, Hoban DJ. Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994; 38:1165.
          </a>
         </li>
         <li class="breakAll">
          Gentamicin (gentamicin sulfate). US FDA approved product information. National Library of Medicine. Available online at www.dailymed.nlm.nih.gov (Accessed on September 25, 2013).
         </li>
         <li class="breakAll">
          Tobramycin (tobramycin sulfate). US FDA approved product information. National Library of Medicine. Available online at www.dailymed.nlm.nih.gov (Accessed on September 25, 2013).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kashuba AD, Nafziger AN, Drusano GL, Bertino JS Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria. Antimicrob Agents Chemother 1999; 43:623.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morris JT, Cooper RH. Intravenous streptomycin: a useful route of administration. Clin Infect Dis 1994; 19:1150.
          </a>
         </li>
         <li class="breakAll">
          ZEMDRI (plazomicin). Package insert. Achaogen, Inc. June, 2018. https://www.zemdri.com/assets/pdf/Prescribing-Information.pdf (Accessed on July 18, 2018).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asempa TE, Kuti JL, Seroogy JD, et al. A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales. Clin Ther 2019; 41:1453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asempa TE, Kuti JL, Seroogy JD, et al. Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection. Antimicrob Agents Chemother 2019; 63.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Isemann BT, Kotagal UR, Mashni SM, et al. Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring. Ther Drug Monit 1996; 18:549.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McDade EJ, Wagner JL, Moffett BS, Palazzi DL. Once-daily gentamicin dosing in pediatric patients without cystic fibrosis. Pharmacotherapy 2010; 30:248.
          </a>
         </li>
         <li class="breakAll">
          Zaske DE. Aminoglycosides. In: Applied Pharmacokinetics, 3rd Ed, William EE, Schentag EJ, Jusko WJ (Eds), Applied Therapeutics Inc, Vancouver, WA 1994.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dager WE, King JH. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing. Ann Pharmacother 2006; 40:9.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roberts JA, Field J, Visser A, et al. Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury. Antimicrob Agents Chemother 2010; 54:3635.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marsot A, Hraiech S, Cassir N, et al. Aminoglycosides in critically ill patients: which dosing regimens for which pathogens? Int J Antimicrob Agents 2020; 56:106124.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buijk SE, Mouton JW, Gyssens IC, et al. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 2002; 28:936.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 475 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM606040.pdf" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Achaogen. Antimicrobial Drugs Advisory Committee Meeting Briefing Book: Plazomicin. May 2, 2018. https://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/Anti-InfectiveDrugsAdvisoryCommittee/UCM606040.pdf (Accessed on July 18, 2018).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="javascript:alert('بدون لینک');" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Trissel LA. Handbook on Injectable Drugs, 14th Ed, American Society of Health-System Pharmacists, Bethesda 2007.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1436333" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Predicting glomerular function from adjusted serum creatinine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8633831" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Once-daily aminoglycoside dosing in immunocompetent adults: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8611830" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Single or multiple daily doses of aminoglycosides: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8734674" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Effectiveness and safety of once-daily aminoglycosides: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8722531" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : A meta-analysis of studies on the safety and efficacy of aminoglycosides given either once daily or as divided doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15231982" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Extended-interval aminoglycoside administration for children: a meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16437518" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : One dose per day compared to multiple doses per day of gentamicin for treatment of suspected or proven sepsis in neonates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22336782" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Once-daily versus multiple-daily dosing with intravenous aminoglycosides for cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15495005" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Antibiotic regimens for endometritis after delivery.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21131321" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Once versus multiple daily dosing of aminoglycosides for patients with febrile neutropenia: a systematic review and meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9753020" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3788968" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : The effect of dosing strategy on kidney cortical accumulation of aminoglycosides in rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3944768" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : In vivo uptake kinetics of aminoglycosides in the kidney cortex of rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10390201" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15708100" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Once versus three-times daily regimens of tobramycin treatment for pulmonary exacerbations of cystic fibrosis--the TOPIC study: a randomised controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31665240" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Plazomicin-associated Nephrotoxicity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16801404" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Absence of cochleotoxicity measured by standard and high-frequency pure tone audiometry in a trial of once- versus three-times-daily tobramycin in cystic fibrosis patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32569143" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Gentamicin Vestibulotoxicity: Further Insights From a Large Clinical Series.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8738765" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Once-daily aminoglycoside dosing: impact on requests and costs for therapeutic drug monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33106864" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrumβ-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26373316" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Infective Endocarditis in Adults: Diagnosis, Antimicrobial Therapy, and Management of Complications: A Scientific Statement for Healthcare Professionals From the American Heart Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9868662" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29441476" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Augmented Renal Clearance in Critically Ill Patients: A Systematic Review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30723936" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Augmented Renal Clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33526481" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Optimizing Aminoglycoside Dosing Regimens for Critically Ill Pediatric Patients with Augmented Renal Clearance: a Convergence of Parametric and Nonparametric Population Approaches.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21651804" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : A comparison of estimates of glomerular filtration in critically ill patients with augmented renal clearance.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36959656" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Onset timing and duration of augmented renal clearance in a mixed intensive care unit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37427084" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Recommendations of Gentamicin Dose Based on Different Pharmacokinetic/Pharmacodynamic Targets for Intensive Care Adult Patients: A Redefining Approach.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36861086" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Impact of the Recent Clinical and Laboratory Standards Institute Breakpoint Changes on the Antimicrobial Spectrum of Aminoglycosides and the Activity of Plazomicin Against Multidrug-Resistant and Carbapenem-Resistant Enterobacterales From United States Medical Centers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34096596" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Pharmacokinetic/pharmacodynamic evaluation of tobramycin dosing in critically ill patients: the Hartford nomogram does not fit.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7793867" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Experience with a once-daily aminoglycoside program administered to 2,184 adult patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30397061" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : A Systematic Review of Single-Dose Aminoglycoside Therapy for Urinary Tract Infection: Is It Time To Resurrect an Old Strategy?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8067757" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8067757" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8067757" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Once-daily aminoglycoside dosing assessed by MIC reversion time with Pseudomonas aeruginosa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10049277" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Optimizing aminoglycoside therapy for nosocomial pneumonia caused by gram-negative bacteria.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7888550" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Intravenous streptomycin: a useful route of administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7888550" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Intravenous streptomycin: a useful route of administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31248681" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : A Simulated Application of the Hartford Hospital Aminoglycoside Dosing Nomogram for Plazomicin Dosing Interval Selection in Patients With Serious Infections Caused by Carbapenem-Resistant Enterobacterales.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31358580" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Application of the Hartford Hospital Nomogram for Plazomicin Dosing Interval Selection in Patients with Complicated Urinary Tract Infection.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8885118" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Optimal gentamicin therapy in preterm neonates includes loading doses and early monitoring.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20180608" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Once-daily gentamicin dosing in pediatric patients without cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20180608" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Once-daily gentamicin dosing in pediatric patients without cystic fibrosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16332944" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20547809" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Using population pharmacokinetics to determine gentamicin dosing during extended daily diafiltration in critically ill patients with acute kidney injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32739478" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Aminoglycosides in critically ill patients: which dosing regimens for which pathogens?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12122533" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Experience with a once-daily dosing program of aminoglycosides in critically ill patients.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
